| Guidelines for the treatment of malaria World Health Organization World Health Organization, 2015 | 6494* | 2015 |
| Anti-infective potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’ P Cos, AJ Vlietinck, DV Berghe, L Maes Journal of ethnopharmacology 106 (3), 290-302, 2006 | 2134 | 2006 |
| Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo G Brackman, P Cos, L Maes, HJ Nelis, T Coenye Antimicrobial agents and chemotherapy 55 (6), 2655-2661, 2011 | 620 | 2011 |
| Leishmania–macrophage interactions: Insights into the redox biology T Van Assche, M Deschacht, RAI da Luz, L Maes, P Cos Free Radical Biology and Medicine 51 (2), 337-351, 2011 | 305 | 2011 |
| Open source drug discovery with the malaria box compound collection for neglected diseases and beyond WC Van Voorhis, JH Adams, R Adelfio, V Ahyong, MH Akabas, P Alano, ... PLoS pathogens 12 (7), e1005763, 2016 | 294 | 2016 |
| In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific … M Vermeersch, RI da Luz, K Toté, JP Timmermans, P Cos, L Maes Antimicrobial agents and chemotherapy 53 (9), 3855-3859, 2009 | 283 | 2009 |
| Extended structure–activity relationship and pharmacokinetic investigation of (4-quinolinoyl) glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP) K Jansen, L Heirbaut, R Verkerk, JD Cheng, J Joossens, P Cos, L Maes, ... Journal of medicinal chemistry 57 (7), 3053-3074, 2014 | 207 | 2014 |
| Advancing drug innovation for neglected diseases—criteria for lead progression S Nwaka, B Ramirez, R Brun, L Maes, F Douglas, R Ridley PLoS neglected tropical diseases 3 (8), e440, 2009 | 199 | 2009 |
| Inhibitory Effect of Biocides on the Viable Masses and Matrices of Staphylococcus aureus and Pseudomonas aeruginosa Biofilms K Toté, T Horemans, DV Berghe, L Maes, P Cos Applied and environmental microbiology 76 (10), 3135-3142, 2010 | 193 | 2010 |
| Biofilms: an extra hurdle for effective antimicrobial therapy P Cos, K Tote, T Horemans, L Maes Current pharmaceutical design 16 (20), 2279-2295, 2010 | 190 | 2010 |
| A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline E Davioud-Charvet, S Delarue, C Biot, B Schwöbel, CC Boehme, ... Journal of medicinal chemistry 44 (24), 4268-4276, 2001 | 185 | 2001 |
| PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome H Van de Ven, C Paulussen, PB Feijens, A Matheeussen, P Rombaut, ... Journal of controlled release 161 (3), 795-803, 2012 | 183 | 2012 |
| Plant substances as anti-HIV agents selected according to their putative mechanism of action P Cos, L Maes, D Vanden Berghe, N Hermans, L Pieters, A Vlietinck Journal of Natural Products 67 (2), 284-293, 2004 | 181 | 2004 |
| Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold K Jansen, L Heirbaut, JD Cheng, J Joossens, O Ryabtsova, P Cos, ... ACS medicinal chemistry letters 4 (5), 491-496, 2013 | 178 | 2013 |
| Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives THM Jonckers, S Van Miert, K Cimanga, C Bailly, P Colson, ... Journal of Medicinal Chemistry 45 (16), 3497-3508, 2002 | 178 | 2002 |
| Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis (9-amino-6-chloro-2-methoxyacridines): influence of the linker S Girault, P Grellier, A Berecibar, L Maes, E Mouray, P Lemiere, ... Journal of medicinal chemistry 43 (14), 2646-2654, 2000 | 169 | 2000 |
| Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent H Imamura, T Downing, F Van den Broeck, MJ Sanders, S Rijal, S Sundar, ... Elife 5, e12613, 2016 | 162 | 2016 |
| Synthesis and in Vitro and in Vivo Antimalarial Activity of N-(7-Chloro-4-quinolyl)-1, 4-bis (3-aminopropyl) piperazine Derivatives A Ryckebusch, R Deprez-Poulain, L Maes, MA Debreu-Fontaine, ... Journal of medicinal chemistry 46 (4), 542-557, 2003 | 157 | 2003 |
| Structure-activity relationship of cinnamaldehyde analogs as inhibitors of AI-2 based quorum sensing and their effect on virulence of Vibrio spp G Brackman, S Celen, U Hillaert, S Van Calenbergh, P Cos, L Maes, ... PLoS One 6 (1), e16084, 2011 | 150 | 2011 |
| Plant-derived leading compounds for chemotherapy of human immunodefiency virus (HIV) infection–an update (1998–2007) P Cos, L Maes, A Vlietinck, L Pieters Planta Medica, 1323-1337, 2008 | 146 | 2008 |
